Genflow Biosciences PLC (LSE: GENF, OTCQB: GENFF) has announced progress across its two core research programmes, bringing it closer to initiating human trials for its gene therapies targeting age-related diseases.
The company confirmed it is preparing its lead candidate, GF-1002, for clinical trial authorisation in Europe—an essential regulatory step before testing in humans can begin. Genflow is working alongside its manufacturing partner, Exothera, to ensure the therapy is produced to Good Manufacturing Practice (GMP) standards, which guarantee product quality and safety.
In parallel, efficacy studies are being conducted by independent research partners Physiogenex and Accelera. These pre-clinical trials are evaluating GF-1002 in early and advanced stages of MASH (metabolic dysfunction-associated steatohepatitis), a form of liver disease.
Genflow’s second programme, GF-1004, is progressing through a proof-of-concept trial in older dogs. The company has submitted a protocol amendment clarifying the intravenous dosage, which aims to minimise infusion-related side effects. The study, which began in March with partner Syngene, tests whether GF-1004—a therapy based on a version of the SIRT6 gene found in long-lived humans—can address age-related decline in canines.
Chief executive Dr Eric Leire said the update reflects the growing maturity of Genflow’s pipeline and its commitment to advancing therapies for healthy ageing. He added that a combination of non-dilutive funding, strategic partnerships, and favourable regulatory conditions puts the company in a strong position to accelerate development.
Genflow remains Europe’s only listed company focused exclusively on longevity science and expects these developments to support upcoming regulatory submissions and further clinical studies.
